Trial Profile
A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Cisplatin; Paclitaxel
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms AGO-Zervix-1
- 28 Mar 2022 This trial has been completed in Belgium (End Date: 02 Apr 2014), according to European Clinical Trials Database record.
- 19 Feb 2022 This trial has been completed in Germany (End Date: 02 Apr 2014), according to European Clinical Trials Database record.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003652).